Post-Doctoral Position:
Improving ADC safety through cancer specific linker cleavage

Context: Antibody-Drug Conjugates (ADCs) are fast growing classes of oncology therapeutics. They consist in a highly potent cytotoxic drug connected via a linker to an antibody that is specifically targeting certain tumor markers. By combining the cytotoxicity of the drug and the targeting properties of the antibody, ADCs aim to kill cancer cells niches whilst leaving healthy cells unaffected. Nine ADCs have already reached the market and the approval of many more is hotly anticipated, with at least 83 candidates in clinical trials.
However, despite a rapid evolution of the field, improvement in ADCs design still exist, which could fuel the development of *new generations*. Among crucial aspects, the specific and efficient delivery of the drug payload exclusively at the expected site of action remains a highly desirable feature.

Project: At BFC, we have identified a novel family of enzyme-sensitive linkers with high effective cleavage in key cell lines. Our objective in this project is to explore the application of this linker to the design of next generation ADC and to establish its superiority over generic linkers in terms of safety and efficacy.

Profile of candidates: We are looking for a highly motivated and creative person willing to break through dogma and to develop new concepts of cancer specific linkers.
The candidate should have demonstrated their expertise in organic synthesis but not necessarily in this specific field. However, an agile spirit, curiosity and the will to work as part of a team in a multidisciplinary environment are essential qualities.

Interested candidates should send document in support of their application to:

Alain Wagner: alwag@unistra.fr and Guilhem Chaubet: chaubet@unistra.fr

Laboratory of BioFunctional Chemistry
Faculté de Pharmacie, UMR 7199 CAMB
74 Route du Rhin, BP60024
F-67401 Illkirch France
Ph 33 368 854 297
Fax 33 368 854 306
alwag@unistra.fr
www.Biofunctional.eu